Medigene to Host Virtual R&D Event on Medigene’s Optimal 3S TCRs for TCR-Guided Precision Immunotherapies
16. September 2024 08:30 ET
|
Medigene AG
Planegg/Martinsried, September 16, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024
14. September 2024 07:30 ET
|
Medigene AG
Planegg/Martinsried, September 14, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene Announces U.S. FDA Clearance of IND Application for MDG1015, a First-in-Class, Third Generation T Cell Receptor Engineered T Cell (TCR-T) Therapy for Multiple Solid Tumor Indications
05. September 2024 08:00 ET
|
Medigene AG
Planegg/Martinsried, September 5, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene AG Secures Two Additional Patents for Technologies in Its End-to-End Platform
29. August 2024 05:00 ET
|
Medigene AG
Planegg/Martinsried, August 29, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene to Present at Upcoming Investor Conferences
28. August 2024 05:00 ET
|
Medigene AG
Planegg/Martinsried, August 28, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene AG implements announced 2:1 share capital reduction and consolidation of the shares effective August 29, 2024
26. August 2024 05:00 ET
|
Medigene AG
Number of shares issued decreases from 29,475,189 to 14,737,594 due consolidation of the shares at a ratio of 2:1Consolidation of shares to take place on August 29, 2024 Planegg/Martinsried,...
Medigene AG Reports Half-Year 2024 Financial Results and Provides Corporate Update
14. August 2024 01:30 ET
|
Medigene AG
Significant corporate and scientific progress in the first half of 2024Advancement of lead program MDG1015 with IND filing on track for 3Q 2024 and CTA filing for 4Q 2024New additions to...
Medigene AG to Report Half-Year 2024 Financial Results on August 14, 2024
08. August 2024 10:15 ET
|
Medigene AG
Planegg/Martinsried, August 8, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene and WuXi Biologics Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers
08. August 2024 04:00 ET
|
Medigene AG
Partnership leverages Medigene’s leadership for T cell receptor (TCR) generation and characterization and WuXi Biologics’ unique anti-CD3 mAb, its T cell engager (TCE) platform and proprietary...
Medigene to Present at ESMO Congress 2024
23. Juli 2024 05:15 ET
|
Medigene AG
Planegg/Martinsried, July 23, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...